Skip to main content
NCBI home page
Gut logoLink to Gut
. 1995 Jan;36(1):50–54. doi: 10.1136/gut.36.1.50

DNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed method for assessing severity of disease.

F Bortoluzzi 1, M Valentini 1, C Cernigoi 1, G Toffoli 1, M Boiocchi 1, M Poletti 1, M Sozzi 1, M Fornasarig 1, R Cannizzaro 1, E Bertolissi 1
PMCID: PMC1382352  PMID: 7890236

Abstract

The assessment of disease severity in ulcerative colitis depends mainly on subjective variables, and an objective method of assessing mucosal inflammation is needed. Determination of the synthetic phase of the cell cycle is an accurate expression of inflammatory activity in the colonic mucosa. The aim of the study was to find out if the proliferative index or the synthetic phase (S phase) of the colonic mucosa of patients with ulcerative colitis, as evaluated by DNA flow cytometry, is a reliable and reproducible marker of disease activity. Sixty consecutive patients with ulcerative colitis of different degrees of activity were entered into the study and submitted to colonoscopy plus multiple rectal biopsies. Disease severity was defined for each patient by means of a clinical, endoscopic, and histological score. Flow cytometry was used to calculate the proliferative index and the S phase of the cell cycle. A statistically significant correlation (p < 0.001) was found between all indices of severity. It is suggested that flow cytometric evaluation of the cell cycle in the rectal mucosa may be an efficient method of assessing severity of disease and efficacy of medical treatment in ulcerative colitis.

Full text

PDF
50

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aslan A., Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol. 1992 Apr;87(4):432–437. [PubMed] [Google Scholar]
  2. BARON J. H., CONNELL A. M., LENNARD-JONES J. E. VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J. 1964 Jan 11;1(5375):89–92. doi: 10.1136/bmj.1.5375.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Børkje B., Høstmark J., Skagen D. W., Schrumpf E., Laerum O. D. Flow cytometry of biopsy specimens from ulcerative colitis, colorectal adenomas, and carcinomas. Scand J Gastroenterol. 1987 Dec;22(10):1231–1237. doi: 10.3109/00365528708996469. [DOI] [PubMed] [Google Scholar]
  4. Campieri M., Gionchetti P., Belluzzi A., Brignola C., Tampieri M., Iannone P., Miglioli M., Barbara L. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut. 1991 Aug;32(8):929–931. doi: 10.1136/gut.32.8.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fochios S. E., Korelitz B. I. The role of sigmoidoscopy and rectal biopsy in diagnosis and management of inflammatory bowel disease: personal experience. Am J Gastroenterol. 1988 Feb;83(2):114–119. [PubMed] [Google Scholar]
  6. Gomes P., du Boulay C., Smith C. L., Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986 Jan;27(1):92–95. doi: 10.1136/gut.27.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hammarberg C., Slezak P., Tribukait B. Early detection of malignancy in ulcerative colitis. A flow-cytometric DNA study. Cancer. 1984 Jan 15;53(2):291–295. doi: 10.1002/1097-0142(19840115)53:2<291::aid-cncr2820530218>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  8. Holmquist L., Ahrén C., Fällström S. P. Clinical disease activity and inflammatory activity in the rectum in relation to mucosal inflammation assessed by colonoscopy. A study of children and adolescents with chronic inflammatory bowel disease. Acta Paediatr Scand. 1990 May;79(5):527–534. doi: 10.1111/j.1651-2227.1990.tb11507.x. [DOI] [PubMed] [Google Scholar]
  9. Korelitz B. I., Sommers S. C. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. Am J Gastroenterol. 1975 Nov;64(5):365–370. [PubMed] [Google Scholar]
  10. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975 Jul;66(1):188–193. doi: 10.1083/jcb.66.1.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lichtiger S., Present D. H. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet. 1990 Jul 7;336(8706):16–19. doi: 10.1016/0140-6736(90)91521-b. [DOI] [PubMed] [Google Scholar]
  12. McCarthy R. C., Fetterhoff T. J. Issues for quality assurance in clinical flow cytometry. Arch Pathol Lab Med. 1989 Jun;113(6):658–666. [PubMed] [Google Scholar]
  13. O'Morain C., Tobin A., Leen E., Suzuki Y., O'Riordan T. Criteria of case definition in Crohn's disease and ulcerative colitis. Scand J Gastroenterol Suppl. 1989;170:7–19. doi: 10.3109/00365528909091340. [DOI] [PubMed] [Google Scholar]
  14. Pera A., Bellando P., Caldera D., Ponti V., Astegiano M., Barletti C., David E., Arrigoni A., Rocca G., Verme G. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology. 1987 Jan;92(1):181–185. [PubMed] [Google Scholar]
  15. Powell-Tuck J., Bown R. L., Lennard-Jones J. E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13(7):833–837. doi: 10.3109/00365527809182199. [DOI] [PubMed] [Google Scholar]
  16. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989 Jan 14;298(6666):82–86. doi: 10.1136/bmj.298.6666.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Riley S. A., Mani V., Goodman M. J., Dutt S., Herd M. E. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991 Feb;32(2):174–178. doi: 10.1136/gut.32.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988 May;29(5):669–674. doi: 10.1136/gut.29.5.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988 Jun;94(6):1383–1389. doi: 10.1016/0016-5085(88)90677-4. [DOI] [PubMed] [Google Scholar]
  20. Rutegård I., Ahsgren L., Stenling R., Nilsson T. A simple index for assessment of disease activity in patients with ulcerative colitis. Hepatogastroenterology. 1990 Dec;37 (Suppl 2):110–112. [PubMed] [Google Scholar]
  21. Rutegård J. N. Assessment profiles of disease severity in ulcerative colitis. Dig Dis. 1993;11(1):32–35. doi: 10.1159/000171398. [DOI] [PubMed] [Google Scholar]
  22. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625–1629. doi: 10.1056/NEJM198712243172603. [DOI] [PubMed] [Google Scholar]
  23. Seo M., Okada M., Yao T., Ueki M., Arima S., Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992 Aug;87(8):971–976. [PubMed] [Google Scholar]
  24. Shapiro H. M. Flow cytometry of DNA content and other indicators of proliferative activity. Arch Pathol Lab Med. 1989 Jun;113(6):591–597. [PubMed] [Google Scholar]
  25. Sninsky C. A., Cort D. H., Shanahan F., Powers B. J., Sessions J. T., Pruitt R. E., Jacobs W. H., Lo S. K., Targan S. R., Cerda J. J. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991 Sep 1;115(5):350–355. doi: 10.7326/0003-4819-115-5-350. [DOI] [PubMed] [Google Scholar]
  26. Sutherland L. R., Martin F., Greer S., Robinson M., Greenberger N., Saibil F., Martin T., Sparr J., Prokipchuk E., Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987 Jun;92(6):1894–1898. doi: 10.1016/0016-5085(87)90621-4. [DOI] [PubMed] [Google Scholar]
  27. TRUELOVE S. C., WITTS L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041–1048. doi: 10.1136/bmj.2.4947.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES